Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.

Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio ® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints.

EAST HANOVER, N.J., April 6, 2024 /PRNewswire/ -- Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio ® (inclisiran) to maximally tolerated statin therapy ...

Novartis’ commercial team has so far reached more than 90% of targeted doctors, the CEO said. For Leqvio’s launch, Novartis is taking a population health-based approach at 200 large U.S ...

Mike Exton, VP and head of the U.S. and global cardiovascular, renal and metabolism franchise at Novartis, sees the ads as hitting different notes than other pharma ads — and ones that are uniquely ...

Novartis has announced new long-term data from its ORION-8 clinical trial. The study is a phase 3 open-label extension of the company’s ORION-9, ORION-10, ORION-11 and ORION-3 trials. Data emerging ...

Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio ® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy ...